LigaChem Biosciences (KOSDAQ:141080) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Dec 21
Have your own idea? Try our Stock Screener
South Korean (KOSPI) Clinical Research and Equipment Industry Analysis
UpdatedDec 31, 2024
DataAggregated Company Financials
Companies30
- 7D0.9%
- 3M-1.2%
- 1Y26.7%
- YTDn/a
Over the last 7 days, the Clinical Research and Equipment industry has remained flat, although notably LigaChem Biosciences gained 12%. As for the the longer term, the industry is up 24% over the past 12 months. As for the next few years, earnings are expected to grow by 20% per annum.
Industry Valuation and Performance
Has the South Korean Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 31 Dec 2024 | ₩75.9t | ₩5.0t | ₩965.6b | 13x | 78.6x | 15.2x |
| Thu, 28 Nov 2024 | ₩75.2t | ₩5.0t | ₩908.5b | 19.1x | 82.7x | 15x |
| Sat, 26 Oct 2024 | ₩84.7t | ₩4.8t | ₩885.3b | 13.1x | 95.6x | 17.5x |
| Mon, 23 Sep 2024 | ₩83.2t | ₩4.8t | ₩885.3b | 14.9x | 93.9x | 17.2x |
| Wed, 21 Aug 2024 | ₩71.6t | ₩4.8t | ₩863.7b | 16.1x | 82.8x | 14.8x |
| Fri, 19 Jul 2024 | ₩67.1t | ₩4.5t | ₩731.7b | 18.2x | 91.8x | 14.8x |
| Sun, 16 Jun 2024 | ₩58.1t | ₩4.6t | ₩691.8b | 19.8x | 84x | 12.6x |
| Tue, 14 May 2024 | ₩61.2t | ₩4.4t | ₩635.1b | 19.7x | 96.4x | 14x |
| Thu, 11 Apr 2024 | ₩63.7t | ₩4.7t | ₩654.7b | 18.8x | 97.2x | 13.7x |
| Sat, 09 Mar 2024 | ₩66.4t | ₩4.6t | ₩635.2b | 34.5x | 104.6x | 14.3x |
| Mon, 05 Feb 2024 | ₩66.7t | ₩4.5t | ₩714.4b | 33.1x | 93.3x | 14.7x |
| Wed, 03 Jan 2024 | ₩62.8t | ₩4.5t | ₩721.5b | 33.4x | 87x | 13.8x |
| Fri, 01 Dec 2023 | ₩57.2t | ₩4.5t | ₩726.0b | 32.4x | 78.8x | 12.6x |
| Sun, 29 Oct 2023 | ₩56.4t | ₩4.4t | ₩660.9b | 21.4x | 85.4x | 12.8x |
| Tue, 26 Sep 2023 | ₩55.1t | ₩4.4t | ₩660.9b | 34x | 83.4x | 12.5x |
| Thu, 24 Aug 2023 | ₩60.1t | ₩4.2t | ₩672.8b | 28.8x | 89.3x | 14.3x |
| Sat, 22 Jul 2023 | ₩58.7t | ₩4.2t | ₩673.4b | 29.2x | 87.2x | 14x |
| Mon, 19 Jun 2023 | ₩60.3t | ₩4.2t | ₩666.5b | 30.1x | 90.4x | 14.2x |
| Wed, 17 May 2023 | ₩61.6t | ₩4.1t | ₩626.3b | 26.5x | 98.4x | 15.1x |
| Fri, 14 Apr 2023 | ₩63.8t | ₩4.1t | ₩626.3b | 30.5x | 101.8x | 15.6x |
| Sun, 12 Mar 2023 | ₩60.7t | ₩4.0t | ₩718.4b | 20.7x | 84.5x | 15.2x |
| Tue, 07 Feb 2023 | ₩63.1t | ₩3.5t | ₩427.8b | 20.9x | 147.5x | 18.1x |
| Thu, 05 Jan 2023 | ₩62.1t | ₩3.4t | ₩428.7b | 22.8x | 144.8x | 18.1x |
| Sat, 03 Dec 2022 | ₩67.3t | ₩3.4t | ₩428.7b | 18.7x | 157x | 19.6x |
| Mon, 31 Oct 2022 | ₩67.8t | ₩3.0t | ₩448.5b | 22.9x | 151.1x | 22.7x |
| Wed, 28 Sep 2022 | ₩59.0t | ₩3.0t | ₩448.5b | 21.5x | 131.4x | 19.8x |
| Fri, 26 Aug 2022 | ₩66.7t | ₩2.9t | ₩479.8b | 26.3x | 138.9x | 22.7x |
| Sun, 24 Jul 2022 | ₩65.6t | ₩2.7t | ₩454.7b | 28.9x | 144.3x | 24.2x |
| Tue, 21 Jun 2022 | ₩64.8t | ₩2.7t | ₩454.7b | 27.6x | 142.5x | 23.9x |
| Thu, 19 May 2022 | ₩63.1t | ₩2.4t | ₩381.0b | 22.2x | 165.7x | 26.1x |
| Sat, 16 Apr 2022 | ₩61.8t | ₩2.4t | ₩379.4b | 24.5x | 163x | 25.5x |
| Mon, 14 Mar 2022 | ₩58.7t | ₩2.4t | ₩392.9b | 25.6x | 149.3x | 24.2x |
| Wed, 09 Feb 2022 | ₩59.7t | ₩2.3t | ₩412.7b | 24.5x | 144.7x | 25.4x |
| Fri, 07 Jan 2022 | ₩64.8t | ₩2.3t | ₩412.7b | n/a | 157.1x | 27.6x |
Price to Earnings Ratio
157.1x
Current Industry PE
- Investors are pessimistic on the South Korean Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 77.1x which is lower than its 3-year average PE of 113x.
- The 3-year average PS ratio of 17.6x is higher than the industry's current PS ratio of 14.9x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have grown 33% per year over the last three years.
- Revenues for these companies have grown 29% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Comparison
How does South Korean Clinical Research and Equipment compare with similar industries?
| KR Market | -1.47% | |
| Healthcare | 1.95% | |
| Life Sciences | 0.91% | |
| Clinical Research and Equipment | 0.91% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| A141080 LigaChem Biosciences | ₩109.00k | 12.0% +₩426.7b | 67.7% | PS39.2x | |
| A087010 Peptron | ₩101.80k | 7.7% +₩150.8b | 152.9% | PS873.6x | |
| A220100 FutureChemLtd | ₩17.31k | 12.6% +₩42.9b | 64.1% | PS24.3x | |
| A002630 ORIENT BIO | ₩1.55k | 22.1% +₩33.2b | 154.9% | n/a | |
| A456070 ENCell | ₩17.30k | 17.8% +₩28.0b | n/a | n/a |
